EP2908791B1 - Heating plaster for the treatment of punctures of jellyfish and other marine animals - Google Patents
Heating plaster for the treatment of punctures of jellyfish and other marine animals Download PDFInfo
- Publication number
- EP2908791B1 EP2908791B1 EP13818397.5A EP13818397A EP2908791B1 EP 2908791 B1 EP2908791 B1 EP 2908791B1 EP 13818397 A EP13818397 A EP 13818397A EP 2908791 B1 EP2908791 B1 EP 2908791B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- plaster
- layer
- use according
- heating
- epidermis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 239000011505 plaster Substances 0.000 title claims description 64
- 238000010438 heat treatment Methods 0.000 title claims description 32
- 241001465754 Metazoa Species 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title claims description 19
- 241000242583 Scyphozoa Species 0.000 title claims description 17
- 239000010410 layer Substances 0.000 claims description 56
- 208000002193 Pain Diseases 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 23
- 210000003491 skin Anatomy 0.000 claims description 21
- 210000002615 epidermis Anatomy 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 241000242759 Actiniaria Species 0.000 claims description 6
- 241001248007 Scorpaena Species 0.000 claims description 6
- -1 aiginates Polymers 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- 230000003444 anaesthetic effect Effects 0.000 claims description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 241001116389 Aloe Species 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- 240000000560 Citrus x paradisi Species 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 235000011399 aloe vera Nutrition 0.000 claims description 2
- 229940003214 aluminium chloride Drugs 0.000 claims description 2
- 230000003501 anti-edematous effect Effects 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 150000002603 lanthanum Chemical class 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920002492 poly(sulfone) Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 229940111630 tea tree oil Drugs 0.000 claims description 2
- 239000010677 tea tree oil Substances 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000000717 retained effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 206010053510 Venomous sting Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000013535 sea water Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002484 nematocyst Anatomy 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000010455 vermiculite Substances 0.000 description 2
- 229910052902 vermiculite Inorganic materials 0.000 description 2
- 235000019354 vermiculite Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000005569 Iron sulphate Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F17/00—First-aid kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
- A61F13/0233—Adhesive bandages or dressings wound covering film layers without a fluid retention layer characterised by the oclusive layer skin contacting layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
- A61F13/0243—Adhesive bandages or dressings wound covering film layers without a fluid retention layer characterised by the properties of the skin contacting layer, e.g. air-vapor permeability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
Definitions
- the present invention relates in general to the pharmaceutical field, and more specifically it refers to a heating plaster for the treatment of punctures of jellyfish and other marine animals, such as scorpion fishes, rays, weevers, sea anemones and similar.
- Jellyfishes are marine animals that are extremely widespread, present in almost all the seas of the world, although the geographical distribution of the several species of jellyfish is different, and different is also their degree of hazard.
- cnidocytes that are activated by contact causing the extroversion of stinging filaments called cnidae.
- These filaments can be of two types, called spirocysts and nematocysts, and are connected to the so-called cnidoblasts, that are organelles containing an stinging liquid having a neurotoxic action.
- composition of the stinging liquid may vary from species to species, but it is generally constituted by a mixture of three proteins: the hypnotoxin having an anesthetic-paralyzing effect; the thalassin, having allergenic action with inflammatory response, and the congestine, having a paralyzing effect on the circulatory and respiratory system.
- the stinging liquid released by stinging jellyfish causes an acute inflammatory reaction, characterized by erythema, swelling, blisters and bubbles, also accompanied by a burning and pain sensation.
- the term “burn”, but also the term “sting”, is often used to indicate the consequences of the contact of the jellyfish stinging liquid with the skin, as it will be in the following description of the invention.
- the immediate, acute reaction is also followed, even at a distance of days or even months from the contact with the animal, by the formation of skin lesions of eczematous type, even serious ones, or of recurrent dermatitis.
- the amount of reactions related to the jellyfish sting is however in any case such as to require an effective and targeted therapeutic treatment, which, however, does not exist today.
- the scientific medical literature on the subject shows that there is still a big "therapeutic confusion" regarding the treatment of jellyfish stings, and any international, officially recognized, therapeutic protocol totally lacks.
- Many people make use of traditional remedies, void of any scientific evidence, that are ineffective, if not even harmful in certain cases; an example is the use of ammonia or urine, the use of washings with freshwater or the use of pressure bandages, all measures that may have harmful effects, resulting in the release of stinging liquid under the skin in larger amount than that released without any treatments.
- WO2004064786 describes an abrasive pad useful for delivering a skin treatment for marine stings, but no external layer is present as heat source.
- the Applicant has now developed a new medical device in the form of a plaster, for use in the treatment of punctures of marine animals able to exert a synergistic and simultaneous action against the various consequences of stings from jellyfish, scorpion fishes, weevers, rays, sea anemones and the like, capable in particular of:
- a plaster for the treatment of punctures of marine animals such as jellyfish, scorpion fishes, weevers, rays, sea anemones and the like, comprising at least two layers, of which a first layer intended for contacting the skin is capable of retaining, incorporating and removing stings or stinging filaments of the animal possibly present in the epidermis, and a second external layer has heating action activated at time of use.
- a kit comprising the present plaster and a device suitable for the removal of stings or filaments, as well as the use of the present plaster or of the kit, represent further subjects of the invention.
- the expression "puncture of animals” means the contact of the stinging animal with a body's epidermis, with consequences that require a therapeutic treatment.
- the first layer of the present plaster intended for contacting the skin, comprises a viscous matrix, consisting essentially of products in form of waxes or gels which are stable at least up to a temperature of approximately 60°C, selected from amongst polysulphones, polycarbonates, polyurethanes, alginates, and synthetic polymers such as polymethacrylates, polysiloxanes and the like.
- this viscous matrix is constituted by a wax or a gel which take a highly viscous consistency following heating, when the outer heating layer activates, while they decrease their viscosity up to solidify when the plaster cools down to body temperature; in this way, during the heating phase, the matrix easily incorporates the filaments that may be present on the epidermis, holding them in the matrix solidified during removal of the patch.
- body temperature a normal temperature of a healthy human body is meant, comprised typically between 36°C and 38°C.
- the layer of the present plaster intended for contacting the skin further comprises one or more active principles having deactivating action of the stinging liquid already injected in the epidermis, and having anti-inflammatory, anaesthetic, astringent and/or soothing action, optionally in combination with agents that improve the active principles' release and passage through the epidermis, and/or with other excipients and/or diluents that are pharmaceutically acceptable and commonly used in this kind of formulations; such active principles are preferably selected from the group consisting of acetic acid, aloe, allantoin, aluminium chloride, lidocaine, benzocaine, cortisonics, thermostable proteolytic enzymes, such as bromelain or papain, calcium or lanthanum salts, grapefruit seed extracts, and Tea Tree oil.
- active principles are preferably selected from the group consisting of acetic acid, aloe, allantoin, aluminium chloride, lidocaine, benzocaine, cortisonics, thermo
- active principles may be formulated in a "traditional" way or in such a way as to obtain a modified, delayed or controlled release, for instance by formulating the active principle in the form of microcapsules or nanoparticles or a similar formulation suitable for modifying the release of the same active principle in the desired way.
- the inner layer of the present plaster besides having a therapeutic action when are present one or more active principles for the local transdermal release, has mainly a "cushion" action, maintaining intact the stinging filaments of the jellyfish or the stings of other animals that may be present in the area to be treated, which remain embedded and protected within a matrix that has high viscosity and constitutes this layer of the plaster. In this way, the breaking of the filaments themselves is avoided, as well as the consequent release of further stinging liquid that would worsen the consequences of the puncture.
- the particular nature of the matrix having a viscosity variable with temperature, causes the filaments that may be present on the epidermis to be retained inside the matrix when removing the plaster. It is a mechanical action whereby the filaments, still intact, remain adherent to the viscous matrix when the plaster is removed, avoiding the release of the stinging liquid contained in the filaments.
- This inner layer of the plaster finally performs an adhesive action, making the plaster adhere to the skin, even per se thanks to the high viscosity matrix, without the need for adhesive edges.
- the present plaster may be further provided with two or more adhesive edges for the adhesion of the plaster to the skin, preferably made with adhesive products such as polysiloxanes, polyacrylates, ethylene-vinyl acetate copolymers, polyurethanes and elastomeric polymers such as polyisobutene.
- adhesive products such as polysiloxanes, polyacrylates, ethylene-vinyl acetate copolymers, polyurethanes and elastomeric polymers such as polyisobutene.
- Particularly suitable to the invention are silicone derivatives in reticular or linear form that well tolerate high temperatures. In general, products that do not create irritation to the skin are preferred.
- the present plaster further comprises an outer heating layer that, at time of use, is activated thus generating a heating up to a maximum temperature of approximately 60°C, preferably up to a temperature ranging between 40 and 50°C, more preferably between 42 and 48°C, for a period of time ranging for instance between 20 and 30 minutes, and preferably shorter than 30 minutes.
- the Applicant has found in particular that the heating action of the plaster on the lesion from jellyfish puncture in such conditions of times and temperature, is able to inactivate the thermolabile proteins present in the stinging liquid injected in the lesion, thus having a first desired therapeutic effect.
- the outer heating layer can be prepared in such a way as to be easily detached from the other layers of the plaster once spent the time of 20-30 minutes considered necessary and sufficient to exert the therapeutic action of the heating, in case the plaster has to be maintained on the skin, for instance because it contains active ingredients in the inner layer that may also act advantageously for longer times.
- the heating layer according to the invention can be prepared for example with a supersaturated aqueous solution of sodium acetate and a sheet of metal of suitable dimensions, inserted inside a casing of plastic material resistant to heat and preferably also capable of catalyzing the exothermic reaction occurring inside it, further distributing the heat over the entire surface of the plaster.
- the supersaturated aqueous solution of sodium acetate can be prepared starting from an aqueous solution obtained by heating at about 100°C sodium acetate trihydrate in the crystalline form, and subsequent cooling to room temperature.
- the heating action of the outer layer can also be provided by two separate housings comprised in the outer layer, respectively comprising water or other suitable liquid and a reagent that, by contact with the liquid, generates heat at the temperature and for the time desired, for instance comprising water and calcium chloride.
- the heating layer can be made from a formulation which, by contact with oxygen in the air, gives rise to a highly exothermic oxidation reaction, thus producing enough heat to raise the temperature to the above said values for the time necessary for the treatment; for instance, such a formulation comprises iron powder, iron sulphate or carbonate, vermiculite, sodium chloride or the like, optionally in the presence of a suitable catalyst of the oxidation reaction.
- An external protective film capable of preventing the passage of air will also be comprised in the plaster, so that the heating layer activates only as a result of the opening of the film, and the passage of oxygen is prevented until use.
- the plaster is manufactured and packaged under protected atmosphere, and then sealed in a special casing impermeable to gases, so as to guarantee the absence of air until use.
- the outer layer comprises electrical microresistances able to produce heat by means of electricity supplied from microbatteries or by connection to the electricity distribution network, inserted inside a plastic heat-resistant casing.
- the present plaster may provide for the union of the two layers, the external heating layer and the inner high viscosity layer, in a single layer in which the electrical microresistances are embedded in a matrix of a viscous heat-resistant polymer, wherein are also possibly present also one or more active ingredients as described above, so that they may also be released through electroporation.
- the present plaster may also comprise a further layer adjacent to the heating layer or to the support layer, if present; this additional layer, called cooling layer, has just the function of cooling the surface of the plaster, and therefore the area to be treated, thanks to appropriate liquids or crystals having thermal action and activated by the rupture of the casing in which they are enclosed.
- This additional layer called cooling layer
- an additional layer is present between the external heating layer and the inner viscous layer, such additional layer having function of support and/or protection of the skin from a possible excessive heat generated by the outer heating layer, and possibly also a function of adhesive to hold the plaster in position on the area of skin to be treated.
- the dimensions of the present plaster may be the most different, so as to adapt it to the various dimensions of lesions, and the thickness is preferably limited in order to facilitate the application of the plaster on the skin.
- the plaster of the invention may have different shapes, such as rectangular, square, ribbon-like, and at least two of its edges may for instance be free from the internal matrix with high viscosity, or this matrix fills the entire surface available of the inner layer.
- the square or rectangular shapes with right angles are preferred, because they allow the continued application of multiple plasters in adjacent areas, also covering very large areas of the body, without leaving any spots uncovered and without the therapeutic action of the plaster.
- the plaster of the invention is preferably sealed inside a suitable protective container until use; this container is made of a material impermeable to substances present on the plaster, adhesive but easily detachable from the plaster.
- a preferred embodiment of the present plaster provides for the use of only transparent materials, so as to maintain, at all times of the treatment, a visual contact also with the lesion, in order to evaluate the progress in real time.
- the present plaster may comprise a temperature indicator, for example an LCD (Liquid Crystals Display) indicator, to facilitate control of the heat generated and to further improve the use of the plaster.
- a temperature indicator for example an LCD (Liquid Crystals Display) indicator
- a plaster according to the present invention may be prepared by using a viscous matrix consisting essentially of calcium and sodium alginate, and polymethacrylate, which is spread on a surface of a polyester support layer, thus forming a uniform viscous layer intended for contacting the skin.
- the opposite surface of this support layer is attached to the external heating layer, that may be prepared with a mixture of iron powder, vermiculite, sodium chloride and active carbon as the catalyst, put inside a plastic film permeable to air.
- This operation is carried out under inert atmosphere, as well as the operation of packaging the so-obtained plaster device in an external protective film made of polypropylene, which prevents the passage of air until use and may be easily broken at time of use to allow air flowing inside the heating layer and trigger the heating action.
- the present plaster may be packaged in a kit together with a plastic device, for example in the shape of tweezers or spatula, suitable for the removal of that part of the stings or stinging filaments retained on the surface and more easily visible, before application of the plaster.
- a plastic device for example in the shape of tweezers or spatula, suitable for the removal of that part of the stings or stinging filaments retained on the surface and more easily visible, before application of the plaster.
- the present plaster for the therapeutic treatment of lesions from contact with jellyfish and other marine animals mentioned above acts in a synergistic way and simultaneously against the various consequences of the contact with the skin, inactivating the injected stinging liquid, composed of thermolabile proteins, thanks to a thermal action, blocking the opening of further filaments or stings of the animal that may be retained on the epidermis and removing them still intact when removing the plaster.
- the optional presence of active ingredients in the inner adhesive layer allows conveying anesthetics, anti-inflammatory, astringent and/or soothing agents on the injured area, with an effective therapy and prevention of damage from burns caused by contact with the animal. Due to its formulation as a plaster, it is a therapeutic mean particularly handy and easy to carry, even in places far from first-aid posts, and it is also easy to use.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Seasonings (AREA)
- Fertilizers (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
- The present invention relates in general to the pharmaceutical field, and more specifically it refers to a heating plaster for the treatment of punctures of jellyfish and other marine animals, such as scorpion fishes, rays, weevers, sea anemones and similar.
- Jellyfishes are marine animals that are extremely widespread, present in almost all the seas of the world, although the geographical distribution of the several species of jellyfish is different, and different is also their degree of hazard.
- Some species present in particular in Australia, Mexico and Southeast Asia, are extremely dangerous; deadly attacks from these species are reported every year for people, while other species, such as those located in the Mediterranean Sea, have a much lower degree of hazard. Nevertheless, even the species considered as most harmless can cause very annoying, inflammatory reactions by simple contact with the skin and, if not treated promptly in an appropriate manner, can give rise to cutaneous, more or less serious, lesions even at a distance of time.
- For all species of jellyfish, such reactions on the skin are caused by contact with the stinging tentacles of the jellyfish, hanging from the lower part of the so-called umbrella-shaped bell, which constitutes the body of the animal. In the tentacles there are special cellular formations called cnidocytes that are activated by contact causing the extroversion of stinging filaments called cnidae. These filaments can be of two types, called spirocysts and nematocysts, and are connected to the so-called cnidoblasts, that are organelles containing an stinging liquid having a neurotoxic action. The composition of the stinging liquid may vary from species to species, but it is generally constituted by a mixture of three proteins: the hypnotoxin having an anesthetic-paralyzing effect; the thalassin, having allergenic action with inflammatory response, and the congestine, having a paralyzing effect on the circulatory and respiratory system.
- More specifically, the stinging liquid released by stinging jellyfish causes an acute inflammatory reaction, characterized by erythema, swelling, blisters and bubbles, also accompanied by a burning and pain sensation. For this reason the term "burn", but also the term "sting", is often used to indicate the consequences of the contact of the jellyfish stinging liquid with the skin, as it will be in the following description of the invention. In certain cases, the immediate, acute reaction is also followed, even at a distance of days or even months from the contact with the animal, by the formation of skin lesions of eczematous type, even serious ones, or of recurrent dermatitis.
- The amount of reactions related to the jellyfish sting is however in any case such as to require an effective and targeted therapeutic treatment, which, however, does not exist today. The scientific medical literature on the subject shows that there is still a big "therapeutic confusion" regarding the treatment of jellyfish stings, and any international, officially recognized, therapeutic protocol totally lacks. Many people make use of traditional remedies, void of any scientific evidence, that are ineffective, if not even harmful in certain cases; an example is the use of ammonia or urine, the use of washings with freshwater or the use of pressure bandages, all measures that may have harmful effects, resulting in the release of stinging liquid under the skin in larger amount than that released without any treatments. This is due to the fact that the filaments containing the stinging liquid, besides releasing the stinging liquid on the skin following to the contact with the animal, are also retained partially by the epidermis and, if not extracted, they may open and release in situ further liquid. The remedies described above just facilitate the opening of filaments, thus worsening the patient's condition.
- Other remedies of the folk medicine, such as the empirical use of a heat source, such as hot surfaces and/or hot objects like rocks, engine parts or tubular inflatable boats, as well as the use of vinegar, of topical anesthetics, or of seawater have instead proved useful, at least to alleviate the pain or to prevent opening of the filaments, which are retained subcutaneously.
-
WO2004064786 describes an abrasive pad useful for delivering a skin treatment for marine stings, but no external layer is present as heat source. - None of the single remedies used until today, however, represent a complete and effective treatment of the consequences of jellyfish stings. To the best knowledge of the Applicant, therefore, it is still felt the need to provide an effective treatment method, which is able to act positively in a synergistic way and simultaneously against the pain, the stinging liquid already injected and the filaments retained in the epidermis.
- The same observations mentioned above can also be made for other marine animals, in addition to jellyfish, such as scorpion fishes, weevers, rays, anemones and the like, that share with the jellyfish the characteristic to inoculate a type of poison constituted by thermolabile proteins and to lose filaments or stings still containing the poison, which may be retained by the epidermis. Even for the bites of these animals, the same traditional treatments have been used until today with similar results to those described above, and with the need, therefore, to develop a method of treatment finally effective against the poison injected by the animal following the puncture, as well as against stings and filaments retained by the epidermis and against the pain caused.
- The Applicant has now developed a new medical device in the form of a plaster, for use in the treatment of punctures of marine animals able to exert a synergistic and simultaneous action against the various consequences of stings from jellyfish, scorpion fishes, weevers, rays, sea anemones and the like, capable in particular of:
- exerting a controlled, localized heating that inactivates the stinging liquid, decomposing the thermolabile protein components of the stinging liquid itself, which thus loses its toxic and stinging action;
- retaining and incorporating any possible stings or filaments of the tentacles of the animal still containing some stinging liquid, thus preventing the release of further stinging liquid;
- further releasing at least one active substance having anesthetic and/or anti-inflammatory and/or astringent and/or soothing action;
- removing, during the removal of the plaster, any stings or filaments possibly incorporated.
- This plaster, then, in addition to fight effectively and at the same time the various negative consequences of the punctures of the above said animals, also represents a highly practical therapeutic product, which brings together different means of treatment in a single product, which is easily transportable and always available.
- It is therefore subject of the present invention a plaster for the treatment of punctures of marine animals such as jellyfish, scorpion fishes, weevers, rays, sea anemones and the like, comprising at least two layers, of which a first layer intended for contacting the skin is capable of retaining, incorporating and removing stings or stinging filaments of the animal possibly present in the epidermis, and a second external layer has heating action activated at time of use.
- A kit comprising the present plaster and a device suitable for the removal of stings or filaments, as well as the use of the present plaster or of the kit, represent further subjects of the invention.
- Further important features of the product of the invention are disclosed in the following detailed description.
- In the present invention, the expression "puncture of animals" means the contact of the stinging animal with a body's epidermis, with consequences that require a therapeutic treatment.
- The first layer of the present plaster, intended for contacting the skin, comprises a viscous matrix, consisting essentially of products in form of waxes or gels which are stable at least up to a temperature of approximately 60°C, selected from amongst polysulphones, polycarbonates, polyurethanes, alginates, and synthetic polymers such as polymethacrylates, polysiloxanes and the like. Typically, this viscous matrix is constituted by a wax or a gel which take a highly viscous consistency following heating, when the outer heating layer activates, while they decrease their viscosity up to solidify when the plaster cools down to body temperature; in this way, during the heating phase, the matrix easily incorporates the filaments that may be present on the epidermis, holding them in the matrix solidified during removal of the patch.
- By the term "body temperature" according to the present invention, a normal temperature of a healthy human body is meant, comprised typically between 36°C and 38°C.
- According to a preferred embodiment of the invention, the layer of the present plaster intended for contacting the skin further comprises one or more active principles having deactivating action of the stinging liquid already injected in the epidermis, and having anti-inflammatory, anaesthetic, astringent and/or soothing action, optionally in combination with agents that improve the active principles' release and passage through the epidermis, and/or with other excipients and/or diluents that are pharmaceutically acceptable and commonly used in this kind of formulations; such active principles are preferably selected from the group consisting of acetic acid, aloe, allantoin, aluminium chloride, lidocaine, benzocaine, cortisonics, thermostable proteolytic enzymes, such as bromelain or papain, calcium or lanthanum salts, grapefruit seed extracts, and Tea Tree oil. These active principles may be formulated in a "traditional" way or in such a way as to obtain a modified, delayed or controlled release, for instance by formulating the active principle in the form of microcapsules or nanoparticles or a similar formulation suitable for modifying the release of the same active principle in the desired way.
- The inner layer of the present plaster, besides having a therapeutic action when are present one or more active principles for the local transdermal release, has mainly a "cushion" action, maintaining intact the stinging filaments of the jellyfish or the stings of other animals that may be present in the area to be treated, which remain embedded and protected within a matrix that has high viscosity and constitutes this layer of the plaster. In this way, the breaking of the filaments themselves is avoided, as well as the consequent release of further stinging liquid that would worsen the consequences of the puncture. This effect is also promoted by the presence of sea water on the epidermis' area to be treated on which the plaster is applied; as a matter of fact, the viscous layer helps retaining on this area sea water, whose saline concentration is known to be useful to prevent opening of the stinging filaments, which are possibly retained subcutaneously.
- Furthermore, the particular nature of the matrix, having a viscosity variable with temperature, causes the filaments that may be present on the epidermis to be retained inside the matrix when removing the plaster. It is a mechanical action whereby the filaments, still intact, remain adherent to the viscous matrix when the plaster is removed, avoiding the release of the stinging liquid contained in the filaments.
- This inner layer of the plaster finally performs an adhesive action, making the plaster adhere to the skin, even per se thanks to the high viscosity matrix, without the need for adhesive edges.
- Alternatively, the present plaster may be further provided with two or more adhesive edges for the adhesion of the plaster to the skin, preferably made with adhesive products such as polysiloxanes, polyacrylates, ethylene-vinyl acetate copolymers, polyurethanes and elastomeric polymers such as polyisobutene. Particularly suitable to the invention are silicone derivatives in reticular or linear form that well tolerate high temperatures. In general, products that do not create irritation to the skin are preferred.
- The present plaster further comprises an outer heating layer that, at time of use, is activated thus generating a heating up to a maximum temperature of approximately 60°C, preferably up to a temperature ranging between 40 and 50°C, more preferably between 42 and 48°C, for a period of time ranging for instance between 20 and 30 minutes, and preferably shorter than 30 minutes. The Applicant has found in particular that the heating action of the plaster on the lesion from jellyfish puncture in such conditions of times and temperature, is able to inactivate the thermolabile proteins present in the stinging liquid injected in the lesion, thus having a first desired therapeutic effect.
- The outer heating layer can be prepared in such a way as to be easily detached from the other layers of the plaster once spent the time of 20-30 minutes considered necessary and sufficient to exert the therapeutic action of the heating, in case the plaster has to be maintained on the skin, for instance because it contains active ingredients in the inner layer that may also act advantageously for longer times.
- The heating layer according to the invention can be prepared for example with a supersaturated aqueous solution of sodium acetate and a sheet of metal of suitable dimensions, inserted inside a casing of plastic material resistant to heat and preferably also capable of catalyzing the exothermic reaction occurring inside it, further distributing the heat over the entire surface of the plaster. The supersaturated aqueous solution of sodium acetate can be prepared starting from an aqueous solution obtained by heating at about 100°C sodium acetate trihydrate in the crystalline form, and subsequent cooling to room temperature. Within the above said casing, when the metal sheet is pressed, a nucleation center forms that causes the crystallization of sodium acetate, which takes the trihydrate crystalline form; this reaction is exothermic and releases the amount of heat needed for the purpose required for the therapeutic plaster of the invention.
- The heating action of the outer layer can also be provided by two separate housings comprised in the outer layer, respectively comprising water or other suitable liquid and a reagent that, by contact with the liquid, generates heat at the temperature and for the time desired, for instance comprising water and calcium chloride.
- Alternatively, the heating layer can be made from a formulation which, by contact with oxygen in the air, gives rise to a highly exothermic oxidation reaction, thus producing enough heat to raise the temperature to the above said values for the time necessary for the treatment; for instance, such a formulation comprises iron powder, iron sulphate or carbonate, vermiculite, sodium chloride or the like, optionally in the presence of a suitable catalyst of the oxidation reaction. An external protective film capable of preventing the passage of air will also be comprised in the plaster, so that the heating layer activates only as a result of the opening of the film, and the passage of oxygen is prevented until use. In this case the plaster is manufactured and packaged under protected atmosphere, and then sealed in a special casing impermeable to gases, so as to guarantee the absence of air until use.
- According to a further embodiment of the invention, the outer layer comprises electrical microresistances able to produce heat by means of electricity supplied from microbatteries or by connection to the electricity distribution network, inserted inside a plastic heat-resistant casing. In this embodiment, the present plaster may provide for the union of the two layers, the external heating layer and the inner high viscosity layer, in a single layer in which the electrical microresistances are embedded in a matrix of a viscous heat-resistant polymer, wherein are also possibly present also one or more active ingredients as described above, so that they may also be released through electroporation.
- According to a particular embodiment of the invention, the present plaster may also comprise a further layer adjacent to the heating layer or to the support layer, if present; this additional layer, called cooling layer, has just the function of cooling the surface of the plaster, and therefore the area to be treated, thanks to appropriate liquids or crystals having thermal action and activated by the rupture of the casing in which they are enclosed. The activation of the two opposite thermal actions, the cooling and heating actions, takes place sequentially, since the heating action is suitable to inactivate the poison prior to the cooling action, which has astringent, anti-edema and anti-inflammatory function useful to treat the epidermis after inactivation of the poison thanks to the heat.
- According to a particular embodiment of the present plaster, an additional layer is present between the external heating layer and the inner viscous layer, such additional layer having function of support and/or protection of the skin from a possible excessive heat generated by the outer heating layer, and possibly also a function of adhesive to hold the plaster in position on the area of skin to be treated.
- The dimensions of the present plaster may be the most different, so as to adapt it to the various dimensions of lesions, and the thickness is preferably limited in order to facilitate the application of the plaster on the skin. The plaster of the invention may have different shapes, such as rectangular, square, ribbon-like, and at least two of its edges may for instance be free from the internal matrix with high viscosity, or this matrix fills the entire surface available of the inner layer. The square or rectangular shapes with right angles are preferred, because they allow the continued application of multiple plasters in adjacent areas, also covering very large areas of the body, without leaving any spots uncovered and without the therapeutic action of the plaster.
- In any case, the plaster of the invention is preferably sealed inside a suitable protective container until use; this container is made of a material impermeable to substances present on the plaster, adhesive but easily detachable from the plaster.
- A preferred embodiment of the present plaster provides for the use of only transparent materials, so as to maintain, at all times of the treatment, a visual contact also with the lesion, in order to evaluate the progress in real time.
- According to a particular embodiment of the present plaster, it may comprise a temperature indicator, for example an LCD (Liquid Crystals Display) indicator, to facilitate control of the heat generated and to further improve the use of the plaster.
- As an example, a plaster according to the present invention may be prepared by using a viscous matrix consisting essentially of calcium and sodium alginate, and polymethacrylate, which is spread on a surface of a polyester support layer, thus forming a uniform viscous layer intended for contacting the skin. The opposite surface of this support layer is attached to the external heating layer, that may be prepared with a mixture of iron powder, vermiculite, sodium chloride and active carbon as the catalyst, put inside a plastic film permeable to air. This operation is carried out under inert atmosphere, as well as the operation of packaging the so-obtained plaster device in an external protective film made of polypropylene, which prevents the passage of air until use and may be easily broken at time of use to allow air flowing inside the heating layer and trigger the heating action.
- The present plaster, as described above, may be packaged in a kit together with a plastic device, for example in the shape of tweezers or spatula, suitable for the removal of that part of the stings or stinging filaments retained on the surface and more easily visible, before application of the plaster.
- In conclusion, the present plaster for the therapeutic treatment of lesions from contact with jellyfish and other marine animals mentioned above acts in a synergistic way and simultaneously against the various consequences of the contact with the skin, inactivating the injected stinging liquid, composed of thermolabile proteins, thanks to a thermal action, blocking the opening of further filaments or stings of the animal that may be retained on the epidermis and removing them still intact when removing the plaster. The optional presence of active ingredients in the inner adhesive layer allows conveying anesthetics, anti-inflammatory, astringent and/or soothing agents on the injured area, with an effective therapy and prevention of damage from burns caused by contact with the animal. Due to its formulation as a plaster, it is a therapeutic mean particularly handy and easy to carry, even in places far from first-aid posts, and it is also easy to use.
Claims (13)
- A plaster for use in the treatment of punctures of marine animals such as jellyfishes, scorpion fishes, weevers, rays, sea anemones and similar, on a body's epidermis comprising at least two layers, of which a first layer intended to contact the skin to be treated is suitable for holding, incorporating and removing stings and stinging filaments of said animals possibly present in the epidermis following said punctures and comprises a matrix consisting essentially of waxes or products which becomes highly viscous by heating at a temperature higher than the body temperature, and then solidify by cooling at the body temperature or at lower temperature, and a second more external layer has a heating action that is activated at time of use for a period of time shorter than 30 minutes.
- The plaster for use according to claim 1, wherein said products are gels stable at temperature up to at least 6(3°C selected from the group consisting of polysulfones, polycarbonates, polyurethanes, aiginates, and synthetic polymers such as polymethacrylates, polysiloxanes and similar.
- The plaster for use according to claims 1-2, further comprising one or more active principles having deactivating action towards a stinging liquid possibly injected by said animals in epidermis, and/or anti-inflammatory, anaesthetic, astringent and/or soothing action.
- The plaster for use according to claim 3, further comprising one or more agents improving delivery and penetration through epidermis of said active principles and/or further pharmaceutically acceptable excipients or diluents.
- The plaster for use according to claim 3, wherein said active principles are selected from the group consisting of acetic acid, aloe, allantoin, aluminium chloride, lidocaine, benzocaine, cortisonics, thermostable proteolytic enzymes, such as bromelain and papain, calcium or lanthanum salts, grapefruit seeds extracts, and Tea Tree oil.
- The plaster for use according to claim 1, wherein said second external layer is activated generating heating to a temperature ranging from 40 and 50°C for a time comprised between 20 and 30 minutes.
- The plaster for use according to claim 6, wherein said temperature ranges between 42 and 48°C.
- The plaster for use according to claims 1-7, wherein said second layer may be removed thus leaving in position on the skin the remaining layers of the plaster.
- The plaster for use according to claims 1-8, further comprising at least a further intermediate layer between said external heating second layer and said internal viscous first layer, said intermediate layer having function of support and/or protection for the skin from any possible excess of heat generated from said external layer.
- The plaster for use according to claims 1-9, further comprising a further layer adjacent to said intermediate layer, if present, or to said heating layer, said further layer having cooling, antiedema, astringent and/or anti-inflammatory function, that may be activated in sequence once the heating action is finished.
- The plaster for use according to claims 1-10, further comprising a temperature indicator.
- The plaster for use according to claim 1, wherein said first and second layer are joined in a single layer comprising electric micro-resistances incorporated in a matrix of a suitable thermoresistant viscous polymer, possibly further comprising one or more active principle having a deactivating action towards the stinging liquid already injected by said marine animal in epidermis, and/or having anti-inflammatory, anaesthetic, astringent and/or soothing action.
- A kit for use in the treatment of punctures of marine animals such as jellyfishes, scorpion fishes, weevers, rays, sea anemones and similar, comprising the plaster for use as described in claims 1-12 and a device suitable for removing stings or stinging filaments of said animals possibly present in epidermis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000211A ITFI20120211A1 (en) | 2012-10-17 | 2012-10-17 | HEATING PATCH FOR THE TREATMENT OF MEDUSA STONES AND OTHER MARINE ANIMALS |
| PCT/IB2013/059428 WO2014060988A2 (en) | 2012-10-17 | 2013-10-17 | Heating plaster for the treatment of punctures of jellyfish and other marine animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2908791A2 EP2908791A2 (en) | 2015-08-26 |
| EP2908791B1 true EP2908791B1 (en) | 2016-10-05 |
Family
ID=47138020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13818397.5A Not-in-force EP2908791B1 (en) | 2012-10-17 | 2013-10-17 | Heating plaster for the treatment of punctures of jellyfish and other marine animals |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2908791B1 (en) |
| IT (1) | ITFI20120211A1 (en) |
| WO (1) | WO2014060988A2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040120989A1 (en) * | 1998-12-29 | 2004-06-24 | Remedy Marketing, Inc. | Article for debridement and detoxification of wounds |
| KR20030068625A (en) * | 2002-02-15 | 2003-08-25 | 백창평 | Disposable heating pack coated with anti-inflammation or analgesia composite |
| DE102004003224A1 (en) * | 2003-02-07 | 2004-08-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal patch for administering a drug at a temperature above skin temperature comprises a drug-impermeable backing layer, a drug-containing silicone-based matrix layer, a release liner and a heating element |
-
2012
- 2012-10-17 IT IT000211A patent/ITFI20120211A1/en unknown
-
2013
- 2013-10-17 EP EP13818397.5A patent/EP2908791B1/en not_active Not-in-force
- 2013-10-17 WO PCT/IB2013/059428 patent/WO2014060988A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ITFI20120211A1 (en) | 2014-04-18 |
| WO2014060988A2 (en) | 2014-04-24 |
| WO2014060988A3 (en) | 2014-06-12 |
| EP2908791A2 (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2272827T3 (en) | TRANSDERMAL THERAPEUTIC PATCH WITH CAPSAICINE AND CAPSAICINE ANALOGS. | |
| JP4909892B2 (en) | System and method for providing treatment to the body | |
| AU784779B2 (en) | Ultraviolet-shielding adhesive preparation | |
| WO2020051117A1 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| ES2683006T3 (en) | Non-aqueous patch | |
| JP4669875B2 (en) | Two patch percutaneous system removably secured to each other for delivering treatment to a body part | |
| US9186334B2 (en) | Heat assisted lidocaine and tetracaine for transdermal analgesia | |
| US20030055475A1 (en) | Product and method for reduction of skin itch, discomfort, and disease | |
| EP2908791B1 (en) | Heating plaster for the treatment of punctures of jellyfish and other marine animals | |
| JPWO2017146096A1 (en) | Patch | |
| CN104053434A (en) | Topical patch for the treatment of mosquito toxicity | |
| US11147775B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
| US20070098769A1 (en) | Systems and methods for treating hot flashes associated with menopause | |
| JPH111428A (en) | Warmth-giving cataplasm sheet | |
| CN108042662A (en) | A kind of medicament for treating scald | |
| US11458324B1 (en) | Cosmetic treatment for reducing body size | |
| EP1097682A2 (en) | Wound dressing | |
| RU2463931C1 (en) | Method of preventing perioperative hypothermia and hyperthermia during operations under general anesthesia | |
| EP3297587B1 (en) | Intravenous access device | |
| CN103239600B (en) | Burn and scald plaster and preparation method thereof | |
| CN111803479A (en) | Formula and using method of scald medicine with pain relieving effect | |
| CN112755038A (en) | Western medicine composition for treating burns and scalds and preparation method thereof | |
| CN102000213A (en) | Traditional Chinese herbal medicine preparation for treating burn | |
| TWM311427U (en) | Hydrocolloid dressing | |
| WO2020211787A1 (en) | Pharmaceutical preparation, system comprising same, preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150505 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20160420 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PONTE, ORSOLINA Inventor name: FIAMINGO, FRANCESCA LIDIA Inventor name: VINCHESI, MASSIMO |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VINCHESI, MASSIMO Inventor name: PONTE, ORSOLINA Inventor name: FIAMINGO, FRANCESCA LIDIA |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 833956 Country of ref document: AT Kind code of ref document: T Effective date: 20161015 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013012580 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161005 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 833956 Country of ref document: AT Kind code of ref document: T Effective date: 20161005 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170106 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170105 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602013012580 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170206 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170205 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170503 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170105 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161017 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20170802 |
|
| 26N | No opposition filed |
Effective date: 20170706 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161205 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161017 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131017 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20171017 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171017 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161005 |